{"id":59841,"date":"2026-02-27T00:26:53","date_gmt":"2026-02-27T00:26:53","guid":{"rendered":"https:\/\/www.globalresearch.co.kr\/insight\/her-2-negative-breast-cancer-market-mordor\/"},"modified":"2026-10-02T22:41:40","modified_gmt":"2026-10-02T13:41:40","slug":"her-2-negative-breast-cancer-market-mordor","status":"publish","type":"post","link":"https:\/\/www.globalresearch.co.kr\/insight\/her-2-negative-breast-cancer-market-mordor\/","title":{"rendered":"\uc138\uacc4\uc758 \uae00\ub85c\ubc8c HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc810\uc720\uc728 \ubd84\uc11d &#8211; \uc131\uc7a5 \ub3d9\ud5a5 \ubc0f \uc804\ub9dd (2026 &#8211; 2031\ub144)"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/her-2-negative-breast-cancer-market_1664180477802_Screenshot_2022-09-26_135039.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.globalresearch.co.kr\/insight\/wp-content\/uploads\/2026\/02\/her-2-negative-breast-cancer-market-size-image-1770819982792.webp\" alt=\"Chart\" class=\"aligncenter size-full\" \/><\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-0\">1. \uc11c\ub860<\/p>\n<ul>\n<li class=\"toc-level-2\">1.1 \uc5f0\uad6c \uac00\uc815 \ubc0f \uc2dc\uc7a5 \uc815\uc758<\/li>\n<li class=\"toc-level-2\">1.2 \uc5f0\uad6c \ubc94\uc704<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-1\">2. \uc5f0\uad6c \ubc29\ubc95\ub860<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-2\">3. \uc694\uc57d<\/p>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-3\">4. \uc2dc\uc7a5 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">4.1 \uc2dc\uc7a5 \uac1c\uc694<\/li>\n<li class=\"toc-level-2\">4.2 \uc2dc\uc7a5 \ub3d9\uc778\n<ul>\n<li class=\"toc-level-3\">4.2.1 \ucd08\uae30 \ub2e8\uacc4 \uc9c8\ubcd1\uc5d0\uc11c \uc815\ubc00 \uc9c4\ub2e8 \ucc44\ud0dd \uc99d\uac00<\/li>\n<li class=\"toc-level-3\">4.2.2 HR \uc591\uc131 \ud558\uc704 \uc138\uadf8\uba3c\ud2b8\uc5d0\uc11c PARP \uc5b5\uc81c\uc81c \uc2b9\uc778 \ud655\ub300<\/li>\n<li class=\"toc-level-3\">4.2.3 \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4\uc5d0 \ub300\ud55c \ubcf4\ud5d8 \uc801\uc6a9 \ud655\ub300<\/li>\n<li class=\"toc-level-3\">4.2.4 \uc2e0\ubcf4\uc870 \uc694\ubc95 \ucc44\ud0dd \uc99d\uac00 (\uc8fc\ub958)<\/li>\n<li class=\"toc-level-3\">4.2.5 \uc885\uc591 \ubd88\uac00\uc9c0\ub860\uc801 \uc784\uc0c1 \uc124\uacc4\ub85c \ud30c\uc774\ud504\ub77c\uc778 \uac00\uc18d\ud654 (\uc8fc\ubaa9\ubc1b\uc9c0 \ubabb\ud558\ub294)<\/li>\n<li class=\"toc-level-3\">4.2.6 AI \uae30\ubc18 \uc784\uc0c1 \ub9e4\uce6d \ud50c\ub7ab\ud3fc\uc73c\ub85c \ub4f1\ub85d \uac1c\uc120 (\uc8fc\ubaa9\ubc1b\uc9c0 \ubabb\ud558\ub294)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.3 \uc2dc\uc7a5 \uc81c\uc57d\n<ul>\n<li class=\"toc-level-3\">4.3.1 TNBC \uba74\uc5ed \uc694\ubc95 \uc790\uc0b0\uc758 \ub192\uc740 \uc774\ud0c8\ub960<\/li>\n<li class=\"toc-level-3\">4.3.2 \uc9c0\uc5ed\uc0ac\ud68c \ud658\uacbd\uc5d0\uc11c ADC\uc758 \ube44\uc6a9-\ud6a8\uacfc \uc6b0\ub824<\/li>\n<li class=\"toc-level-3\">4.3.3 \uc800\uc18c\ub4dd \uc2dc\uc7a5\uc5d0\uc11c \uc81c\ud55c\uc801\uc778 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac\uc728 (\uc8fc\ubaa9\ubc1b\uc9c0 \ubabb\ud558\ub294)<\/li>\n<li class=\"toc-level-3\">4.3.4 \ubcf5\ud569 \uc694\ubc95\uc5d0 \ub300\ud55c \uc9c0\ubd88\uc790\uc758 \uc555\ub825 \uc99d\uac00 (\uc8fc\ubaa9\ubc1b\uc9c0 \ubabb\ud558\ub294)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">4.4 \uac00\uce58 \/ \uacf5\uae09\ub9dd \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">4.5 \uaddc\uc81c \ud658\uacbd<\/li>\n<li class=\"toc-level-2\">4.6 \uae30\uc220 \uc804\ub9dd<\/li>\n<li class=\"toc-level-2\">4.7 \ud3ec\ud130\uc758 5\uac00\uc9c0 \uacbd\uc7c1 \uc694\uc778\n<ul>\n<li class=\"toc-level-3\">4.7.1 \uc2e0\uaddc \uc9c4\uc785\uc790\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.2 \uacf5\uae09\uc5c5\uccb4\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.3 \uad6c\ub9e4\uc790\uc758 \uad50\uc12d\ub825<\/li>\n<li class=\"toc-level-3\">4.7.4 \ub300\uccb4\uc7ac\uc758 \uc704\ud611<\/li>\n<li class=\"toc-level-3\">4.7.5 \uc0b0\uc5c5 \ub0b4 \uacbd\uc7c1<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-4\">5. \uc2dc\uc7a5 \uaddc\ubaa8 \ubc0f \uc131\uc7a5 \uc608\uce21<\/p>\n<ul>\n<li class=\"toc-level-2\">5.1 \uce58\ub8cc \uc720\ud615\ubcc4 (\uac00\uce58)\n<ul>\n<li class=\"toc-level-3\">5.1.1 \ud654\ud559 \uc694\ubc95<\/li>\n<li class=\"toc-level-3\">5.1.2 \ub0b4\ubd84\ube44 \uc694\ubc95<\/li>\n<li class=\"toc-level-3\">5.1.3 \ud45c\uc801 \uce58\ub8cc (PARP, PI3K, AKT, ADCs)<\/li>\n<li class=\"toc-level-3\">5.1.4 \uba74\uc5ed \uc694\ubc95<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.2 \ubc14\uc774\uc624\ub9c8\ucee4 \ud558\uc704 \uc720\ud615\ubcc4 (\uac00\uce58)\n<ul>\n<li class=\"toc-level-3\">5.2.1 HR-\uc591\uc131 \/ HER2-\uc74c\uc131<\/li>\n<li class=\"toc-level-3\">5.2.2 \uc0bc\uc911 \uc74c\uc131 \uc720\ubc29\uc554 (TNBC)<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.3 \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4 (\uac00\uce58)\n<ul>\n<li class=\"toc-level-3\">5.3.1 \ubcd1\uc6d0<\/li>\n<li class=\"toc-level-3\">5.3.2 \uc804\ubb38 \uc554 \uc13c\ud130<\/li>\n<li class=\"toc-level-3\">5.3.3 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<li class=\"toc-level-2\">5.4 \uc9c0\uc5ed\ubcc4 (\uac00\uce58)\n<ul>\n<li class=\"toc-level-3\">5.4.1 \ubd81\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.1.1 \ubbf8\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.1.2 \uce90\ub098\ub2e4<\/li>\n<li class=\"toc-level-3\">5.4.2 \uc720\ub7fd<\/li>\n<li class=\"toc-level-4\">5.4.2.1 \ub3c5\uc77c<\/li>\n<li class=\"toc-level-4\">5.4.2.2 \uc601\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.2.3 \ud504\ub791\uc2a4<\/li>\n<li class=\"toc-level-4\">5.4.2.4 \uc774\ud0c8\ub9ac\uc544<\/li>\n<li class=\"toc-level-4\">5.4.2.5 \uc2a4\ud398\uc778<\/li>\n<li class=\"toc-level-4\">5.4.2.6 \uc720\ub7fd \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.4.3 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591<\/li>\n<li class=\"toc-level-4\">5.4.3.1 \uc911\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.2 \uc778\ub3c4<\/li>\n<li class=\"toc-level-4\">5.4.3.3 \uc77c\ubcf8<\/li>\n<li class=\"toc-level-4\">5.4.3.4 \ub300\ud55c\ubbfc\uad6d<\/li>\n<li class=\"toc-level-4\">5.4.3.5 \ud638\uc8fc<\/li>\n<li class=\"toc-level-4\">5.4.3.6 \uc544\uc2dc\uc544 \ud0dc\ud3c9\uc591 \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.4.4 \ub0a8\ubbf8<\/li>\n<li class=\"toc-level-4\">5.4.4.1 \ube0c\ub77c\uc9c8<\/li>\n<li class=\"toc-level-4\">5.4.4.2 \uc544\ub974\ud5e8\ud2f0\ub098<\/li>\n<li class=\"toc-level-4\">5.4.4.3 \ub0a8\ubbf8 \uae30\ud0c0<\/li>\n<li class=\"toc-level-3\">5.4.5 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.5.1 GCC<\/li>\n<li class=\"toc-level-4\">5.4.5.2 \ub0a8\uc544\ud504\ub9ac\uce74<\/li>\n<li class=\"toc-level-4\">5.4.5.3 \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74 \uae30\ud0c0<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-5\">6. \uacbd\uc7c1 \ud658\uacbd<\/p>\n<ul>\n<li class=\"toc-level-2\">6.1 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4<\/li>\n<li class=\"toc-level-2\">6.2 \uc2dc\uc7a5 \uc810\uc720\uc728 \ubd84\uc11d<\/li>\n<li class=\"toc-level-2\">6.3 \uae30\uc5c5 \ud504\ub85c\ud544 (\uae00\ub85c\ubc8c \uac1c\uc694, \uc2dc\uc7a5 \uac1c\uc694, \ud575\uc2ec \ubd80\ubb38, \uac00\uc6a9 \uc7ac\ubb34 \uc815\ubcf4, \uc804\ub7b5 \uc815\ubcf4, \uc8fc\uc694 \uae30\uc5c5 \uc2dc\uc7a5 \uc21c\uc704\/\uc810\uc720\uc728, \uc81c\ud488 &amp; \uc11c\ube44\uc2a4, \ucd5c\uadfc \ub3d9\ud5a5 \ud3ec\ud568)\n<ul>\n<li class=\"toc-level-3\">6.3.1 \ub85c\uc288<\/li>\n<li class=\"toc-level-3\">6.3.2 \ud654\uc774\uc790<\/li>\n<li class=\"toc-level-3\">6.3.3 \ub178\ubc14\ud2f0\uc2a4<\/li>\n<li class=\"toc-level-3\">6.3.4 \uc544\uc2a4\ud2b8\ub77c\uc81c\ub124\uce74<\/li>\n<li class=\"toc-level-3\">6.3.5 \uc77c\ub77c\uc774 \ub9b4\ub9ac<\/li>\n<li class=\"toc-level-3\">6.3.6 \uba38\ud06c &amp; \ucf54.<\/li>\n<li class=\"toc-level-3\">6.3.7 \uae38\ub9ac\uc5b4\ub4dc \uc0ac\uc774\uc5b8\uc2a4<\/li>\n<li class=\"toc-level-3\">6.3.8 \ube0c\ub9ac\uc2a4\ud1a8 \ub9c8\uc774\uc5b4\uc2a4 \uc2a4\ud045<\/li>\n<li class=\"toc-level-3\">6.3.9 \uc2dc\uc820<\/li>\n<li class=\"toc-level-3\">6.3.10 \ub2e4\uc774\uc774\ucc0c \uc0b0\ucfc4<\/li>\n<li class=\"toc-level-3\">6.3.11 \uc560\ube0c\ube44<\/li>\n<li class=\"toc-level-3\">6.3.12 \uc554\uc820<\/li>\n<li class=\"toc-level-3\">6.3.13 \uc0ac\ub178\ud53c<\/li>\n<li class=\"toc-level-3\">6.3.14 \uc5d0\uc790\uc774<\/li>\n<li class=\"toc-level-3\">6.3.15 \ud14c\ubc14<\/li>\n<li class=\"toc-level-3\">6.3.16 \ub9e4\ud06c\ub85c\uc81c\ub2c9\uc2a4<\/li>\n<li class=\"toc-level-3\">6.3.17 \ud478\ub9c8 \ubc14\uc774\uc624\ud14c\ud06c\ub180\ub85c\uc9c0<\/li>\n<li class=\"toc-level-3\">6.3.18 \uc820\ub9d9<\/li>\n<li class=\"toc-level-3\">6.3.19 \ubca0\uc774\uc9c4<\/li>\n<li class=\"toc-level-3\">6.3.20 \uc820\ud0c8\ub9ac\uc2a4 \ud30c\ub9c8<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p class=\"toc-level-1 toc-content-heading\" id=\"toc-content-heading-6\">7. \uc2dc\uc7a5 \uae30\ud68c \ubc0f \ubbf8\ub798 \uc804\ub9dd<\/p>\n","protected":false},"excerpt":{"rendered":"<p>HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2dc\uc7a5\uc740 2025\ub144 18\uc5b5 2\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0\uc11c 2026\ub144 19\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec\ub85c \uc131\uc7a5\ud588\uc73c\uba70, 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 8.12%\ub97c \uae30\ub85d\ud558\uba70 2031\ub144\uc5d0\ub294 29\uc5b5 1\ucc9c\ub9cc \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \uc774\ub7ec\ud55c \uc131\uc7a5\uc740 \uc815\ubc00 \uc9c4\ub2e8, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC)\uc758 \uc801\uc751\uc99d \ud655\ub300, \uadf8\ub9ac\uace0 HER2-low \uc885\uc591\uc744 \uc0c8\ub85c\uc6b4 \uce58\ub8cc \ubc94\uc8fc\ub85c \uc778\uc2dd\ud558\ub294 \uacbd\ud5a5\uc774 \ubcf5\ud569\uc801\uc73c\ub85c \uc791\uc6a9\ud558\uc5ec \uac00\uc18d\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uac1c\uc694 \ubc0f \uc8fc\uc694 \ud1b5\uacc4:<br \/>\n*   \uc5f0\uad6c \uae30\uac04: 2020\ub144 \u2013 2031\ub144<br \/>\n*   2026\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 19\uc5b5 7\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   2031\ub144 \uc2dc\uc7a5 \uaddc\ubaa8: 29\uc5b5 1\ucc9c\ub9cc \ub2ec\ub7ec<br \/>\n*   \uc131\uc7a5\ub960 (2026-2031): 8.12% CAGR<br \/>\n*   \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\ub294 \uc2dc\uc7a5: \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591<br \/>\n*   \uac00\uc7a5 \ud070 \uc2dc\uc7a5: \ubd81\ubbf8<br \/>\n*   \uc2dc\uc7a5 \uc9d1\uc911\ub3c4: \ub0ae\uc74c<\/p>\n<p>\ud638\ub974\ubaac \uc218\uc6a9\uccb4 \uc591\uc131\/HER2 \uc74c\uc131 \uc885\uc591\uc740 \uc804\uccb4 \uc720\ubc29\uc554 \ubc1c\uc0dd \uc0ac\ub840\uc758 70%\ub97c \ucc28\uc9c0\ud558\uba70, \uc0bc\uc911\uc74c\uc131 \uc720\ubc29\uc554(TNBC)\uc740 15~20%\ub97c \ucc28\uc9c0\ud558\uc9c0\ub9cc \ubbf8\ucda9\uc871 \uc218\uc694\uac00 \ub192\uc740 \ubd84\uc57c\uc785\ub2c8\ub2e4. PARP \uc5b5\uc81c\uc81c \ubc0f \ucc28\uc138\ub300 ADC\uac00 \uae30\uc874 \ud654\ud559\uc694\ubc95\uc744 \ub300\uccb4\ud558\uba74\uc11c \ud45c\uc801 \uce58\ub8cc\ubc95\uc774 \uac00\uc7a5 \ube60\ub974\uac8c \ucc44\ud0dd\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\uc5ed\uc801\uc73c\ub85c\ub294 \uc720\ubc29\uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00\uc640 \uc815\ubc00 \uc758\ud559 \uc811\uadfc\uc131 \ud5a5\uc0c1\uc73c\ub85c \uc778\ud574 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc73c\ub85c \uc2dc\uc7a5\uc758 \ubaa8\uba58\ud140\uc774 \uc774\ub3d9\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uc9c0\ubd88\uc790\ub4e4\uc740 \ud601\uc2e0\uc744 \uc800\ud574\ud558\uc9c0 \uc54a\uc73c\uba74\uc11c \ube44\uc6a9\uc744 \uc5b5\uc81c\ud558\uae30 \uc704\ud574 \uac00\uce58 \uae30\ubc18 \uc0c1\ud658 \ubc0f \uc801\uc751\uc99d\ubcc4 \uac00\uaca9 \ucc45\uc815\uc744 \ub3c4\uc785\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \ubcf4\uace0\uc11c \uc694\uc57d:<br \/>\n*   \uce58\ub8cc \uc720\ud615\ubcc4: 2025\ub144 \ud654\ud559\uc694\ubc95\uc774 HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2dc\uc7a5\uc758 41.10%\ub97c \ucc28\uc9c0\ud588\uc73c\ub098, \ud45c\uc801 \uce58\ub8cc\ub294 2031\ub144\uae4c\uc9c0 9.02%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<br \/>\n*   \ubc14\uc774\uc624\ub9c8\ucee4 \ud558\uc704 \uc720\ud615\ubcc4: 2025\ub144 \ud638\ub974\ubaac \uc218\uc6a9\uccb4 \uc591\uc131\/HER2 \uc74c\uc131 \uc885\uc591\uc774 57.25%\ub97c \ucc28\uc9c0\ud588\uc73c\uba70, \uc0bc\uc911\uc74c\uc131 \uc720\ubc29\uc554\uc740 2031\ub144\uae4c\uc9c0 9.42%\uc758 CAGR\ub85c \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: 2025\ub144 \ubcd1\uc6d0\uc774 53.10%\ub97c \ucc28\uc9c0\ud588\uc73c\ub098, \uc804\ubb38 \uc554 \uc13c\ud130\ub294 2031\ub144\uae4c\uc9c0 9.95%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\ubcc4: 2025\ub144 \ubd81\ubbf8\uac00 41.85%\uc758 \ub9e4\ucd9c \uc810\uc720\uc728\ub85c \uc2dc\uc7a5\uc744 \uc120\ub3c4\ud588\uc73c\uba70, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591\uc740 2031\ub144\uae4c\uc9c0 10.35%\uc758 CAGR\ub85c \uac00\uc7a5 \ub192\uc740 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \ub3d9\ud5a5 \ubc0f \uc8fc\uc694 \ub3d9\uc778:<br \/>\n*   \ucd08\uae30 \ub2e8\uacc4 \uc9c8\ud658\uc5d0\uc11c \uc815\ubc00 \uc9c4\ub2e8 \ucc44\ud0dd \uc99d\uac00: Oncotype DX\uc640 \uac19\uc740 \uc720\uc804\uccb4 \uac80\uc0ac\ub294 \ucd08\uae30 \ub2e8\uacc4 \ud658\uc790\uc758 \uce58\ub8cc \uad8c\uace0\ub97c \ubcc0\uacbd\ud558\uace0 \ud654\ud559\uc694\ubc95 \uc0ac\uc6a9\uc744 \uc904\uc600\uc2b5\ub2c8\ub2e4. AI \ubaa8\ub378\uc740 \uce58\ub8cc \ubc18\uc751\uc744 91%\uc758 \uc815\ud655\ub3c4\ub85c \uc608\uce21\ud558\uba70, \uc815\ubc00 \uc9c4\ub2e8\uc740 \uacfc\uc789 \uce58\ub8cc\ub97c \uc904\uc774\uace0 \uace0\uc704\ud5d8 \ud658\uc790\ub97c \uc870\uae30\uc5d0 \uc2dd\ubcc4\ud558\uc5ec \uc2dc\uc7a5 \uc131\uc7a5\uc744 \ucd09\uc9c4\ud569\ub2c8\ub2e4.<br \/>\n*   HR-\uc591\uc131 \uc9c8\ud658\uc5d0\uc11c PARP \uc5b5\uc81c\uc81c \uc2b9\uc778 \ud655\ub300: Olaparib\uc758 BRCA \ubcc0\uc774 \uace0\uc704\ud5d8 \ucd08\uae30 HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2b9\uc778\uc740 PARP \uc5b5\uc81c\uc81c\uc758 \uc801\uc6a9 \ubc94\uc704\ub97c \ud655\ub300\ud588\uc2b5\ub2c8\ub2e4. Talazoparib\ub294 \uc911\uad6d\uacfc \ubbf8\uad6d\uc5d0\uc11c \ube44\uc6a9 \ud6a8\uc728\uc131\uc744 \uc785\uc99d\ud588\uc73c\uba70, CDK4\/6 \uc5b5\uc81c\uc81c \ub610\ub294 \uba74\uc5ed\uc694\ubc95\uacfc\uc758 \ubcd1\uc6a9 \uc784\uc0c1 \uc2dc\ud5d8\uc740 \uc2dc\ub108\uc9c0 \ud6a8\uacfc\ub97c \ubcf4\uc5ec PARP \uc5b5\uc81c\uc81c\uac00 \ud575\uc2ec \uce58\ub8cc\ubc95\uc73c\ub85c \uc790\ub9ac\ub9e4\uae40\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADC) \uc0c1\ud658 \ud655\ub300: Trastuzumab deruxtecan\uc758 HER2-low \uc9c8\ud658 \uc2b9\uc778\uc73c\ub85c HR-\uc591\uc131\/HER2 \uc74c\uc131 \uc0ac\ub840\uc758 \uc57d 90%\uac00 \uce58\ub8cc \ub300\uc0c1\uc774 \ub418\uc5c8\uc2b5\ub2c8\ub2e4. Datopotamab deruxtecan\uc740 \ud654\ud559\uc694\ubc95 \ub300\ube44 \uc9c8\ubcd1 \uc9c4\ud589 \uc704\ud5d8\uc744 37% \uac10\uc18c\uc2dc\ucf30\uc2b5\ub2c8\ub2e4. \uc9c0\ubd88\uc790\ub4e4\uc774 \uac00\uce58\uc5d0 \ub530\ub978 \ubcf4\uc7a5\uc744 \ud655\ub300\ud568\uc5d0 \ub530\ub77c ADC \uc0c1\ud658\uc774 \uc99d\uac00\ud558\uc5ec \uc2dc\uc7a5\uc744 \uac15\ud654\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc120\ud589 \ubcf4\uc870 \uc694\ubc95(Neoadjuvant therapy) \ucc44\ud0dd \uc99d\uac00: I-SPY2.2 \uc784\uc0c1 \uc2dc\ud5d8\uc740 datopotamab deruxtecan\uacfc durvalumab \ubcd1\uc6a9\uc774 \ucd08\uae30 \ub2e8\uacc4 \uc9c8\ud658\uc5d0\uc11c \uac15\ub825\ud55c \ubc18\uc751\uc744 \ubcf4\uc784\uc744 \uc785\uc99d\ud588\uc2b5\ub2c8\ub2e4. \uac1c\uc778 \ub9de\ucda4\ud615 \uc120\ud589 \ubcf4\uc870 \uc804\ub7b5\uc740 \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \uc870\uae30 \uc218\uc694\ub97c \ucc3d\ucd9c\ud558\uace0 \uc2dc\uc7a5\uc744 \ud655\ub300\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc81c\uc57d \uc694\uc778:<br \/>\n*   \uc0bc\uc911\uc74c\uc131 \uc720\ubc29\uc554(TNBC) \uba74\uc5ed\uc694\ubc95 \uc790\uc0b0\uc758 \ub192\uc740 \uc2e4\ud328\uc728: Pembrolizumab\uc740 PD-L1 \uc591\uc131 TNBC \ud658\uc790\uc5d0\uac8c\ub9cc \uc0dd\uc874\uc728 \uac1c\uc120\uc744 \ubcf4\uc600\uc73c\uba70, \uba74\uc5ed \uad00\ubb38 \uc5b5\uc81c\uc81c\ub294 \ubc18\uc751\ub960\uc774 \ub0ae\uace0 \ubcd1\uc6a9 \uc694\ubc95 \uc2dc \ub3c5\uc131\uc774 \uc99d\uac00\ud569\ub2c8\ub2e4. \ud30c\uc774\ud504\ub77c\uc778\uc758 \uc704\ucd95\uc740 TNBC \uc2dc\uc7a5 \ud655\uc7a5\uc744 \ub454\ud654\uc2dc\ud0b5\ub2c8\ub2e4.<br \/>\n*   \uc9c0\uc5ed\uc0ac\ud68c \ud658\uacbd\uc5d0\uc11c ADC\uc758 \ube44\uc6a9-\ud6a8\uc728\uc131 \uc6b0\ub824: Trastuzumab deruxtecan\uc758 \ub192\uc740 \ube44\uc6a9-\ud6a8\uacfc\uc131 \ube44\uc728(ICER)\uc740 \uc9c0\ubd88\uc790 \uae30\uc900\uc744 \ucd08\uacfc\ud558\uba70, ADC \uad00\ub828 \uac04\uc9c8\uc131 \ud3d0 \uc9c8\ud658(ILD) \uad00\ub9ac\uc758 \uc5b4\ub824\uc6c0\uacfc HER2-low \ubd84\ub958\uc758 \uc804\ubb38\uc131 \uc694\uad6c\ub294 \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud569\ub2c8\ub2e4.<br \/>\n*   \uc800\uc18c\ub4dd \uc2dc\uc7a5\uc758 \uc81c\ud55c\uc801\uc778 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac\uc728: \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74, \ub77c\ud2f4 \uc544\uba54\ub9ac\uce74 \uc9c0\uc5ed\uc5d0\uc11c\ub294 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac \uc778\ud504\ub77c\uac00 \ubd80\uc871\ud558\uc5ec \ubcf5\uc7a1\ud55c \ud45c\uc801 \uce58\ub8cc\uc81c\uc758 \ub3c4\uc785\uc774 \uc9c0\uc5f0\ub429\ub2c8\ub2e4.<br \/>\n*   \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \uc9c0\ubd88\uc790\uc758 \uc555\ub825 \uc99d\uac00: \ubd81\ubbf8 \ubc0f \uc720\ub7fd\uc5d0\uc11c \uc774\uc911 \uc81c\uc870\uc0ac \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \ub0ae\uc740 \uc0c1\ud658 \uc2b9\uc778\uc740 \ubc88\ub4e4 \uac00\uaca9 \ucc45\uc815\uc5d0 \ub300\ud55c \uc9c0\ubd88\uc790\uc758 \uc6b0\ub824\ub97c \ubc18\uc601\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc138\uadf8\uba3c\ud2b8 \ubd84\uc11d:<br \/>\n*   \uce58\ub8cc \uc720\ud615\ubcc4: \ud654\ud559\uc694\ubc95\uc740 \uc5ec\uc804\ud788 \uc0c1\ub2f9\ud55c \uc810\uc720\uc728\uc744 \ucc28\uc9c0\ud558\uc9c0\ub9cc, PARP \uc5b5\uc81c\uc81c, CDK4\/6 \uc5b5\uc81c\uc81c, ADC, \uba74\uc5ed\uc694\ubc95 \ub4f1 \ud45c\uc801 \uce58\ub8cc\ubc95\uc774 \ub354 \uae34 \ubb34\uc9c4\ud589 \uc0dd\uc874 \uae30\uac04\uacfc \uc801\uc740 \uc804\uc2e0 \ub3c5\uc131\uc73c\ub85c \uc778\ud574 \uce58\ub8cc \uc54c\uace0\ub9ac\uc998\uc744 \ubcc0\ud654\uc2dc\ud0a4\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ub0b4\ubd84\ube44 \uc694\ubc95\uc740 HR-\uc591\uc131 \uc9c8\ud658\uc758 \ud575\uc2ec \uce58\ub8cc\ubc95\uc73c\ub85c \ub0a8\uc544\uc788\uc9c0\ub9cc, \ub0b4\uc131\uc73c\ub85c \uc778\ud574 \ucc28\uc138\ub300 \uc57d\ubb3c \uc218\uc694\uac00 \uc99d\uac00\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ubc14\uc774\uc624\uc2dc\ubc00\ub7ec\uc758 \ub4f1\uc7a5\uc740 \uac00\uaca9 \uc555\ub825\uc744 \uac00\ud558\uc9c0\ub9cc, \ucca8\ub2e8 \ud45c\uc801 \uc694\ubc95\uc740 \ucc28\ubcc4\ud654\ub41c \ud6a8\ub2a5\uc744 \ud1b5\ud574 \ud504\ub9ac\ubbf8\uc5c4 \uac00\uaca9\uc744 \uc720\uc9c0\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ubc14\uc774\uc624\ub9c8\ucee4 \ud558\uc704 \uc720\ud615\ubcc4: HR-\uc591\uc131\/HER2 \uc74c\uc131 \uc885\uc591\uc774 \uc2dc\uc7a5\uc758 \ub300\ubd80\ubd84\uc744 \ucc28\uc9c0\ud558\uc9c0\ub9cc, \uc0bc\uc911\uc74c\uc131 \uc720\ubc29\uc554(TNBC)\uc740 Sacituzumab govitecan\uacfc pembrolizumab \ubcd1\uc6a9 \uc694\ubc95\uc758 \uc131\uacf5 \ubc0f TROP-2, LIV-1 \ub4f1 \uc0c8\ub85c\uc6b4 ADC \uac1c\ubc1c\ub85c \uc778\ud574 \uac00\uc7a5 \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. HR-\uc591\uc131 \uc9c8\ud658\uc5d0\uc11c\ub294 inavolisib\uc640 \uac19\uc740 \ud601\uc2e0\uc774 \ub0b4\ubd84\ube44 \ubc0f CDK4\/6 \uc694\ubc95\uc5d0 \ub300\ud55c \ub0b4\uc131\uc744 \uadf9\ubcf5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \ucd5c\uc885 \uc0ac\uc6a9\uc790\ubcc4: \ubcd1\uc6d0\uc774 \uc2dc\uc7a5 \ub9e4\ucd9c\uc758 \ub300\ubd80\ubd84\uc744 \ucc28\uc9c0\ud558\uc9c0\ub9cc, \uc815\ubc00 \uc885\uc591\ud559\uc758 \ubcf5\uc7a1\uc131(\uc720\uc804\uccb4 \uac80\uc0ac, \ub2e4\ud559\uc81c \ud300, \ucca8\ub2e8 \ub3c5\uc131 \uad00\ub9ac)\uc73c\ub85c \uc778\ud574 \uc804\ubb38 \uc554 \uc13c\ud130\uac00 \ube60\ub974\uac8c \uc131\uc7a5\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. AI \uae30\ubc18 \uc784\uc0c1 \uc2dc\ud5d8 \ub9e4\uce6d \uc2dc\uc2a4\ud15c\uc740 \uc804\ubb38 \uc13c\ud130\uc5d0\uc11c \ube60\ub974\uac8c \ucc44\ud0dd\ub418\uace0 \uc788\uc73c\uba70, \uc774\ub294 \ubcf5\uc7a1\ud55c HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc0ac\ub840\uac00 \uc804\ubb38 \uc13c\ud130\ub85c \uc9d1\uc911\ub418\ub294 \uacbd\ud5a5\uc744 \uac15\ud654\ud569\ub2c8\ub2e4.<\/p>\n<p>\uc9c0\uc5ed \ubd84\uc11d:<br \/>\n*   \ubd81\ubbf8: \uc815\ubc00 \uc9c4\ub2e8\uc758 \uc870\uae30 \ucc44\ud0dd, \uac15\ub825\ud55c \uc784\uc0c1 \uc2dc\ud5d8 \uc0dd\ud0dc\uacc4, FDA\uc758 \uc2e0\uc18d\ud55c \uc2b9\uc778\uc73c\ub85c \uc2dc\uc7a5\uc744 \uc120\ub3c4\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \uadf8\ub7ec\ub098 \uc9c0\ubd88\uc790\ub4e4\uc740 ADC\uc758 \ube44\uc6a9-\ud6a8\uc728\uc131\uc5d0 \uc758\ubb38\uc744 \uc81c\uae30\ud558\uba70 \ub2e8\uacc4\ubcc4 \uce58\ub8cc \ud504\ub85c\ud1a0\ucf5c\uc744 \ub3c4\uc785\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4.<br \/>\n*   \uc720\ub7fd: \uc131\uc219\ud55c \uac74\uac15 \uae30\uc220 \ud3c9\uac00(HTA) \ud504\ub808\uc784\uc6cc\ud06c\uc640 \ubc94\uc720\ub7fd \uaddc\uc81c \uc870\uc815\uc744 \ud1b5\ud574 \uc2dc\uc7a5\uc774 \ubc1c\uc804\ud558\uace0 \uc788\uc2b5\ub2c8\ub2e4. \ud558\uc9c0\ub9cc \uc774\uc911 \uc81c\uc870\uc0ac \ubcd1\uc6a9 \uc694\ubc95\uc5d0 \ub300\ud55c \ub0ae\uc740 \uc0c1\ud658 \uc2b9\uc778\uc740 \uc9c0\ubd88\uc790\uc758 \ubc88\ub4e4 \uac00\uaca9 \ucc45\uc815 \uc6b0\ub824\ub97c \ubc18\uc601\ud569\ub2c8\ub2e4. \ub3d9\uc720\ub7fd \uc2dc\uc7a5\uc740 \ubc14\uc774\uc624\ub9c8\ucee4 \uac80\uc0ac \uc778\ud504\ub77c\uac00 \ubd80\uc871\ud569\ub2c8\ub2e4.<br \/>\n*   \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591: \uc720\ubc29\uc554 \ubc1c\ubcd1\ub960 \uc99d\uac00\ub85c \uc778\ud574 10.35%\uc758 CAGR\ub85c \uac00\uc7a5 \ub192\uc740 \uc131\uc7a5\ub960\uc744 \ubcf4\uc785\ub2c8\ub2e4. \uc77c\ubcf8\uc758 \uc2e0\uc18d\ud55c \uaddc\uc81c \uc2b9\uc778\uacfc \uc911\uad6d\uc758 \uc720\ubc29\uc554 \uce58\ub8cc \ube44\uc6a9 \uae09\uc99d\uc740 \uc774 \uc9c0\uc5ed \uc2dc\uc7a5\uc758 \uc911\uc694\uc131\uc744 \uac15\uc870\ud569\ub2c8\ub2e4. \ud0dc\uad6d\uc758 Pathum Raksa \uc774\ub2c8\uc154\ud2f0\ube0c\uc640 \uac19\uc740 \uacf5\uacf5-\ubbfc\uac04 \ubaa8\ub378\uc740 \uac80\uc0ac \uc5ed\ub7c9 \ud655\ub300\ub97c \uc704\ud55c \ubaa8\ubc94 \uc0ac\ub840\ub97c \uc81c\uc2dc\ud569\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd:<br \/>\n\uc815\ubc00 \uc811\uadfc \ubc29\uc2dd\uc774 \uae30\uc874 \ud654\ud559\uc694\ubc95\uc744 \ub300\uccb4\ud558\uba74\uc11c \uacbd\uc7c1\uc774 \uc2ec\ud654\ub418\uace0 \uc788\uc2b5\ub2c8\ub2e4. CDK4\/6 \uc5b5\uc81c\uc81c(palbociclib, ribociclib, abemaciclib)\uac00 HR-\uc591\uc131 \uce58\ub8cc\ub97c \uc9c0\ubc30\ud558\uc9c0\ub9cc, \ud2b9\ud5c8 \ub9cc\ub8cc \uc2dc \ubc14\uc774\uc624\uc2dc\ubc00\ub7ec\uc758 \uc704\ud611\uc774 \uc788\uc2b5\ub2c8\ub2e4. ADC \uac1c\ubc1c\uc0ac\ub4e4\uc740 TROP-2, LIV-1, HER3 \ub4f1 \uc0c8\ub85c\uc6b4 \ud45c\uc801\uc744 \ucd94\uad6c\ud558\uba70, trastuzumab deruxtecan\uc758 HER2-low \uc885\uc591 \uc131\uacf5\uc740 \ud6c4\uc18d \ud504\ub85c\uadf8\ub7a8 \uac1c\ubc1c\uc744 \ucd09\uc9c4\ud588\uc2b5\ub2c8\ub2e4. \ubcd1\uc6a9 \uc694\ubc95 \uac1c\ubc1c\uc740 \ubd84\uc790 \ub3d9\uc778\uc5d0 \ub9de\ucdb0 \ub0b4\uc131 \ubc1c\ud604\uc744 \uc9c0\uc5f0\uc2dc\ud0a4\ub294 \uac83\uc744 \ubaa9\ud45c\ub85c \ud569\ub2c8\ub2e4. AI\ub97c \ud65c\uc6a9\ud55c \uae30\uc220 \ud30c\ud2b8\ub108\uc2ed\uc740 \uc784\uc0c1 \uc2dc\ud5d8 \ubaa8\uc9d1 \uae30\uac04\uc744 \ub2e8\ucd95\ud558\uace0 \ud3ec\ud2b8\ud3f4\ub9ac\uc624 \uc0dd\uc0b0\uc131\uc744 \ud5a5\uc0c1\uc2dc\ud0b5\ub2c8\ub2e4. \uac00\uaca9 \uc555\ub825\uc740 \ud504\ub9ac\ubbf8\uc5c4 \uc57d\ubb3c \ube44\uc6a9\uacfc \uc81c\ud55c\ub41c \uc758\ub8cc \uc608\uc0b0 \uc131\uc7a5\uc744 \uc870\ud654\uc2dc\ud0a4\uae30 \uc704\ud574 \uc801\uc751\uc99d\ubcc4 \uac00\uaca9 \ucc45\uc815 \ubc0f \uac00\uce58 \uae30\ubc18 \uacc4\uc57d\uc744 \ucd09\uc9c4\ud569\ub2c8\ub2e4. \ubc14\uc774\uc624\uc2dc\ubc00\ub7ec\ub294 \uac00\uaca9\uc744 \ub0ae\ucd94\uaca0\uc9c0\ub9cc, ADC\uc758 \ubcf5\uc7a1\ud55c \uc81c\uc870 \uacfc\uc815\uc740 \uc720\uc0ac\ud55c \uc5ed\ud559 \uad00\uacc4\ub97c \uc9c0\uc5f0\uc2dc\ud0b5\ub2c8\ub2e4. \uc804\ubc18\uc801\uc73c\ub85c HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2dc\uc7a5\uc740 \ud601\uc2e0 \uae30\uc5c5\ub4e4\uc774 \uc0c8\ub85c\uc6b4 \ubd84\uc790 \ud2c8\uc0c8\uc2dc\uc7a5\uc744 \uc120\uc810\ud558\uae30 \uc704\ud574 \uacbd\uc7c1\ud558\uba74\uc11c\ub3c4 \uae30\uc874 \uc2dc\uc7a5\uc744 \ubc29\uc5b4\ud558\ub824\ub294 \ub178\ub825\uc73c\ub85c \uc778\ud574 \ub0ae\uc740 \uc9d1\uc911\ub3c4\ub97c \ubcf4\uc785\ub2c8\ub2e4.<\/p>\n<p>\uc8fc\uc694 \uae30\uc5c5:<br \/>\nEli Lilly and Company, AstraZeneca, GSK, Novartis AG, Pfizer<\/p>\n<p>\ucd5c\uadfc \uc0b0\uc5c5 \ub3d9\ud5a5:<br \/>\n*   2025\ub144 4\uc6d4: AstraZeneca\ub294 \ucd08\uae30 \ub2e8\uacc4 \uc0bc\uc911\uc74c\uc131 \ub610\ub294 HR-low\/HER2 \uc74c\uc131 \uc9c8\ud658 \ud658\uc790\ub97c \ub300\uc0c1\uc73c\ub85c datopotamab deruxtecan\uacfc durvalumab \ubcd1\uc6a9\uc758 3\uc0c1 TROPION-Breast04 \uc120\ud589 \ubcf4\uc870 \uc5f0\uad6c\ub97c \uc2dc\uc791\ud588\uc2b5\ub2c8\ub2e4.<br \/>\n*   2025\ub144 1\uc6d4: FDA\ub294 \ub0b4\ubd84\ube44 \uc694\ubc95 \ubc0f \ud654\ud559\uc694\ubc95 \ud6c4 \uc808\uc81c \ubd88\uac00\ub2a5\ud558\uac70\ub098 \uc804\uc774\uc131 HR-\uc591\uc131, HER2 \uc74c\uc131 \uc9c8\ud658\uc5d0 \ub300\ud574 DATROWAY\ub97c \uc2b9\uc778\ud588\uc73c\uba70, \uc774\ub294 \ud654\ud559\uc694\ubc95 \ub300\ube44 \uc9c8\ubcd1 \uc9c4\ud589 \uc704\ud5d8\uc744 37% \uac10\uc18c\uc2dc\ud0a4\ub294 \ud6a8\uacfc\ub97c \ubcf4\uc600\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 HER-2 \uc74c\uc131 \uc720\ubc29\uc554 \uc2dc\uc7a5\uc5d0 \ub300\ud55c \ud3ec\uad04\uc801\uc778 \ubd84\uc11d\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4. HER-2 \uc74c\uc131 \uc720\ubc29\uc554\uc740 \uc804\uccb4 \uc720\ubc29\uc554\uc758 \uc57d 15%\ub97c \ucc28\uc9c0\ud558\uba70, 2026\ub144 19.7\uc5b5 \ub2ec\ub7ec \uaddc\ubaa8\uc600\ub358 \uc2dc\uc7a5\uc740 2031\ub144\uae4c\uc9c0 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960(CAGR) 8.12%\ub97c \uae30\ub85d\ud558\uba70 29.1\uc5b5 \ub2ec\ub7ec\uc5d0 \uc774\ub97c \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4.<\/p>\n<p>\uc2dc\uc7a5 \uc131\uc7a5\uc744 \uacac\uc778\ud558\ub294 \uc8fc\uc694 \uc694\uc778\uc73c\ub85c\ub294 \ucd08\uae30 \ub2e8\uacc4 \uc9c8\ubcd1 \uc9c4\ub2e8\uc744 \uc704\ud55c \uc815\ubc00 \uc9c4\ub2e8 \ucc44\ud0dd \uc99d\uac00, HR \uc591\uc131 \ud558\uc704 \uc138\uadf8\uba3c\ud2b8\uc5d0\uc11c PARP \uc5b5\uc81c\uc81c \uc2b9\uc778 \ud655\ub300, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4(ADCs)\uc5d0 \ub300\ud55c \ubcf4\ud5d8 \uc801\uc6a9 \ud655\ub300, \uc2e0\ubcf4\uc870 \uc694\ubc95\uc758 \ubcf4\ud3b8\ud654, \uc885\uc591 \ube44\ud2b9\uc774\uc801 \uc784\uc0c1 \uc124\uacc4\ub85c \uc778\ud55c \ud30c\uc774\ud504\ub77c\uc778 \uac00\uc18d\ud654, \uadf8\ub9ac\uace0 AI \uae30\ubc18 \uc784\uc0c1 \ub9e4\uce6d \ud50c\ub7ab\ud3fc\uc744 \ud1b5\ud55c \ud658\uc790 \ub4f1\ub85d \uac1c\uc120 \ub4f1\uc774 \uc788\uc2b5\ub2c8\ub2e4.<\/p>\n<p>\ubc18\uba74, \uc2dc\uc7a5 \uc131\uc7a5\uc744 \uc800\ud574\ud558\ub294 \uc694\uc778\uc73c\ub85c\ub294 \uc0bc\uc911 \uc74c\uc131 \uc720\ubc29\uc554(TNBC) \uba74\uc5ed\uce58\ub8cc\uc81c \uc790\uc0b0\uc758 \ub192\uc740 \uc2e4\ud328\uc728, \uc9c0\uc5ed\uc0ac\ud68c \ud658\uacbd\uc5d0\uc11c ADCs\uc758 \ube44\uc6a9-\ud6a8\uacfc\uc5d0 \ub300\ud55c \uc6b0\ub824, \uc800\uc18c\ub4dd \uc2dc\uc7a5\uc5d0\uc11c\uc758 \uc81c\ud55c\uc801\uc778 \uc0dd\uccb4\ud45c\uc9c0\uc790 \uac80\uc0ac\uc728, \uadf8\ub9ac\uace0 \ubcf5\ud569 \uc694\ubc95\uc5d0 \ub300\ud55c \uc9c0\ubd88\uc790 \uc555\ub825 \uc99d\uac00 \ub4f1\uc774 \uc5b8\uae09\ub429\ub2c8\ub2e4.<\/p>\n<p>\ubcf8 \ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5\uc744 \uce58\ub8cc \uc720\ud615(\ud654\ud559\uc694\ubc95, \ub0b4\ubd84\ube44 \uc694\ubc95, \ud45c\uc801 \uc694\ubc95, \uba74\uc5ed \uc694\ubc95), \uc0dd\uccb4\ud45c\uc9c0\uc790 \ud558\uc704 \uc720\ud615(HR \uc591\uc131\/HER2 \uc74c\uc131, \uc0bc\uc911 \uc74c\uc131 \uc720\ubc29\uc554), \ucd5c\uc885 \uc0ac\uc6a9\uc790(\ubcd1\uc6d0, \uc804\ubb38 \uc554 \uc13c\ud130, \uae30\ud0c0), \uadf8\ub9ac\uace0 \uc9c0\uc5ed(\ubd81\ubbf8, \uc720\ub7fd, \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591, \ub0a8\ubbf8, \uc911\ub3d9 \ubc0f \uc544\ud504\ub9ac\uce74)\ubcc4\ub85c \uc138\ubd84\ud654\ud558\uc5ec \ubd84\uc11d\ud569\ub2c8\ub2e4.<\/p>\n<p>\ud2b9\ud788, \ud45c\uc801 \uc694\ubc95(PARP \uc5b5\uc81c\uc81c, CDK4\/6 \uc5b5\uc81c\uc81c, \ud56d\uccb4-\uc57d\ubb3c \uc811\ud569\uccb4 \ud3ec\ud568)\uc740 2026\ub144\ubd80\ud130 2031\ub144\uae4c\uc9c0 9.02%\uc758 \uac00\uc7a5 \ube60\ub978 \uc5f0\ud3c9\uade0 \uc131\uc7a5\ub960\uc744 \ubcf4\uc77c \uac83\uc73c\ub85c \uc608\uc0c1\ub429\ub2c8\ub2e4. \uc9c0\uc5ed\ubcc4\ub85c\ub294 \uc544\uc2dc\uc544-\ud0dc\ud3c9\uc591 \uc9c0\uc5ed\uc774 \uc9c8\ubcd1 \ubc1c\uc0dd\ub960 \uc99d\uac00, \uc2e0\uc18d\ud55c \uaddc\uc81c \uc2b9\uc778, \uc815\ubc00 \uc758\ud559 \uc811\uadfc\uc131 \ud655\ub300\ub85c \uc778\ud574 10.35%\uc758 \uac00\uc7a5 \ub192\uc740 CAGR\uc744 \uae30\ub85d\ud560 \uac83\uc73c\ub85c \uc804\ub9dd\ub429\ub2c8\ub2e4. \ucd5c\uc885 \uc0ac\uc6a9\uc790 \uce21\uba74\uc5d0\uc11c\ub294 \ubcf5\uc7a1\ud55c \uc0dd\uccb4\ud45c\uc9c0\uc790 \uac80\uc0ac, \ub2e4\ud559\uc81c \uc9c4\ub8cc, ADC \uad00\ub828 \ub3c5\uc131 \uad00\ub9ac\uc758 \ud544\uc694\uc131\uc73c\ub85c \uc778\ud574 \uc804\ubb38 \uc554 \uc13c\ud130\uac00 9.95%\uc758 CAGR\ub85c \uc131\uc7a5\ud560 \uac83\uc73c\ub85c \uc608\uce21\ub429\ub2c8\ub2e4.<\/p>\n<p>\uacbd\uc7c1 \ud658\uacbd \ubd84\uc11d\uc5d0\uc11c\ub294 \uc2dc\uc7a5 \uc9d1\uc911\ub3c4, \uc8fc\uc694 \uae30\uc5c5\uc758 \uc2dc\uc7a5 \uc810\uc720\uc728, \uadf8\ub9ac\uace0 Roche, Pfizer, Novartis, AstraZeneca \ub4f1 20\uac1c \uc8fc\uc694 \uae30\uc5c5\uc758 \uc0c1\uc138 \ud504\ub85c\ud544\uc744 \ub2e4\ub8f9\ub2c8\ub2e4. \ub610\ud55c, \ubcf4\uace0\uc11c\ub294 \uc2dc\uc7a5 \uae30\ud68c\uc640 \ubbf8\ub798 \uc804\ub9dd, \ud2b9\ud788 \ubbf8\ucda9\uc871 \uc218\uc694 \ud3c9\uac00\uc5d0 \ub300\ud55c \ud1b5\ucc30\ub825\uc744 \uc81c\uacf5\ud569\ub2c8\ub2e4.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-59841","post","type-post","status-publish","format-standard","hentry","category-market-reports"],"_links":{"self":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/59841"}],"collection":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/comments?post=59841"}],"version-history":[{"count":0,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/posts\/59841\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/media?parent=59841"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/categories?post=59841"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.globalresearch.co.kr\/insight\/wp-json\/wp\/v2\/tags?post=59841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}